ArticleScientific reports2026
Prenatal exposure to oral glucocorticoids and risk of long-term neurodevelopmental disorders.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
2 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
We investigated whether prenatal exposure to oral glucocorticoids (GCs) is associated with long-term neurodevelopmental disorders (LNDDs) in offspring. Using South Korea’s National Health Insurance Service database, we identified all live births from January 1, 2011, to December 31, 2014 (n = 1,553,505) and followed offspring through December 31, 2023. Maternal oral GC exposure during pregnancy defined the exposed group. After 1:10 propensity-score matching, 33,940 exposed and 338,921 unexposed offspring were analyzed. LNDD incidence was 11.5% in the GC group versus 9.8% in the unexposed group (odds ratio [OR] 1.20, 95% confidence interval [CI], 1.16–1.24; P < 0.001). In duration analyses from the full cohort, adjusted odds were 1.06 (95% CI, 1.05–1.08; P < 0.001) for 1–6 days and 1.13 (95% CI, 1.08–1.19; P < 0.001) for ≥ 7 days versus none. By timing, adjusted odds were 1.21 (95% CI, 1.15–1.27; P < 0.001) for first, 1.16 (95% CI, 1.07–1.26; P < 0.001) for second, and 1.21 (95% CI, 1.14–1.28; P < 0.001) for third trimester exposure. Prenatal exposure to oral GCs was associated with a modest increase in LNDD risk; given the observational design and potential residual confounding, these findings are hypothesis-generating and should inform—rather than prescribe—clinical decision-making.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.